- ISIN
- US19240Q2012
- CUSIP
- 19240Q201
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 29, 2018
Highlights
- Market Cap
- $2.21B
- Enterprise Value
- $2.21B
- EPS (TTM)
- -$3.89
- Gross Profit (TTM)
- -$2.33M
- EBITDA (TTM)
- -$363.18M
- Year Range
- $5.49 - $43.73
- Target Price
- $48.13
- ROA (TTM)
- -39.24%
- ROE (TTM)
- -58.30%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
COGT Performance Chart
Cogent Biosciences, Inc. (COGT) is down 7.8% since the beginning of the year. At $33 per share, COGT is trading 25.1% below its 52-week high of $44. Investors who bought $1,000 worth of COGT shares 5 years ago would now be looking at an investment worth $4,099.
Loading charts...
Returns By Period
Cogent Biosciences, Inc. (COGT) has returned -7.77% so far this year and 483.96% over the past 12 months.
Cogent Biosciences, Inc.
- 1D
- -5.89%
- 1M
- -10.57%
- YTD
- -7.77%
- 6M
- -15.96%
- 1Y
- 483.96%
- 3Y*
- 36.19%
- 5Y*
- 32.60%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
COGT Monthly Returns History
Based on dividend-adjusted daily data since Mar 29, 2018, COGT's average daily return is +0.25%, while the average monthly return is +5.54%. At this rate, an investment would double in approximately 1.1 years.
Historically, 42% of months were positive and 58% were negative. The best month was Jul 2020 with a return of +484.8%, while the worst month was Nov 2019 at -43.8%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 9 months.
On a daily basis, COGT closed higher 47% of trading days. The best single day was Jul 6, 2020 with a return of +394.4%, while the worst single day was Dec 11, 2023 at -53.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.10% | 8.19% | -0.93% | -7.01% | -2.32% | -6.29% | -7.77% | ||||||
| 2025 | 19.36% | -19.12% | -20.45% | -13.02% | 4.41% | 31.99% | 59.05% | 5.78% | 18.87% | 13.51% | 146.75% | -11.69% | 355.38% |
| 2024 | -24.66% | 58.01% | -4.00% | -3.27% | 23.23% | 5.24% | 11.86% | 13.89% | 0.56% | 6.39% | -17.23% | -17.98% | 32.65% |
| 2023 | 30.28% | -12.15% | -18.44% | -0.28% | 9.11% | 0.85% | 9.71% | -6.00% | -20.15% | -16.31% | -6.00% | -23.34% | -49.13% |
| 2022 | -11.89% | -21.56% | 26.31% | -14.29% | -28.19% | 95.66% | 22.95% | 48.69% | -9.52% | -8.51% | -7.84% | -8.11% | 34.73% |
| 2021 | -21.91% | -10.60% | 11.99% | -1.03% | -0.35% | -6.35% | -26.02% | 38.00% | 1.57% | 0.83% | -6.60% | 8.33% | -23.60% |
Benchmark Metrics
Cogent Biosciences, Inc. has an annualized alpha of 60.86%, beta of 1.11, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since April 02, 2018.
- This stock participated in 152.97% of S&P 500 Index downside but only 93.95% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 60.86%
- Beta
- 1.11
- R²
- 0.02
- Upside Capture
- 93.95%
- Downside Capture
- 152.97%
Return for Risk
Risk / Return Rank
COGT ranks 98 for risk / return — in the top 98% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Cogent Biosciences, Inc. (COGT) and compare them to S&P 500 Index.
| COGT | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 3.74 | 2.39 | +1.35 |
Sortino ratioReturn per unit of downside risk | 7.85 | 3.25 | +4.60 |
Omega ratioGain probability vs. loss probability | 1.92 | 1.43 | +0.49 |
Calmar ratioReturn relative to maximum drawdown | 18.93 | 3.11 | +15.81 |
Martin ratioReturn relative to average drawdown | 47.83 | 14.38 | +33.45 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cogent Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cogent Biosciences, Inc. was 98.09%, occurring on Mar 16, 2020. The portfolio has not yet recovered.
The current Cogent Biosciences, Inc. drawdown is 51.16%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
COVID crash2020 | -98.09%Mar 2020 | 1y 7mo | — | 7y 10moAug 2018 - now |
2018 correction2018 | -14.94%May 2018 | 17d | 20d | 1mo 7dApr 2018 - May 2018 |
2018 correction2018 | -14.54%Jul 2018 | 1d | 14d | 15dJul 2018 - Jul 2018 |
2018 correction2018 | -11.18%Jun 2018 | 0s | 22d | 22dJun 2018 - Jul 2018 |
2018 correction2018 | -10.98%Jun 2018 | 7d | 5d | 12dJun 2018 - Jun 2018 |
Drawdown Indicators
| COGT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.09% | -56.78% | -41.31% |
Max Drawdown (1Y)Largest decline over 1 year | -25.79% | -9.10% | -16.69% |
Max Drawdown (3Y)Largest decline over 3 years | -69.87% | -18.90% | -50.97% |
Max Drawdown (5Y)Largest decline over 5 years | -76.34% | -25.43% | -50.91% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -51.16% | 0.00% | -51.16% |
Average DrawdownAverage peak-to-trough decline | -77.83% | -10.72% | -67.11% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.18% | 1.97% | +8.21% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cogent Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cogent Biosciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for COGT in comparison with other companies in the Biotechnology industry. Currently, COGT has a P/B value of 3.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with COGT
Add Cogent Biosciences, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with COGT